Fahad Mukhtar

Fahad Mukhtar

Auto-generated profile, based on publicly available information

Fahad Mukhtar

Stanley Research Program Sheppard Pratt Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2016 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
FMFahad Mukhtar
Fahad Mukhtar
PBPaolo Boffetta
Paolo Boffetta
HRHarvey A. Risch
Harvey A. Risch
JPJong Y. Park
Jong Y. Park
OBOmonigho Bubu
Omonigho Bubu
HLHung N. Luu
Hung N. Luu
Burkitt's Lymphoma (BL) has three peaks of occurrence, in children, adults and elderly, at 10, 40 and 70 years respectively. To the best of our knowledge, no study has been conducted to assess predictors of survival in the three age groups. We hypothesized that survival predictors may differ by age group. We, therefore, sought to determine survival predictors for BL in these three groups: children (70 years of age). Using the Surveillance, Epidemiology, and End Results (SEER) database covering the years 2000‐2013, we identified 797 children, 1,994 adults and 757 elderly patients newly diagnosed with BL. We used adjusted Cox proportional hazards regression models to determine prognostic factors for survival for each age group. Five‐year relative survival in BL for children, adults and elderly were 90.4, 47.8 and 28.9%, respectively. Having at least Stage II disease and multiple primaries were associated with higher mortality in the elderly group. In adults, multiple primaries, Stage III or IV disease, African American race and bone marrow primary were associated with increased mortality whereas Stage IV disease and multiple primaries were associated with worse outcome in children. These findings demonstrate commonalities and differences in predictors of survival that may have implications for management of BL patients.

2 January 2021 in African Journal of AIDS Research
Verified
Journal Article
Closed access
FDFarouq Dayyab
Farouq Dayyab
FMFahad Mukhtar
Fahad Mukhtar
GIGarba Iliyasu
Garba Iliyasu
AHAbdulrazaq Habib
Abdulrazaq Habib
Background: Considerable success has been recorded in the global fight against the human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS). Retention in care is the key to ...

19 August 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OUOvie Utuama
Ovie Utuama
FMFahad Mukhtar
Fahad Mukhtar
YPYen Thi-Hai Pham
Yen Thi-Hai Pham
BDBashir Dabo
Bashir Dabo
PMPriyashi Manani
Priyashi Manani
HLHUNG LUU
HUNG LUU
There has been marked improvement in leukemia survival, particularly among children in recent time. However, the long-term trends in survival among adult leukemia patients and the associated sex and racial survival disparities are not well understood. We, therefore, evaluated the secular trends in survival improvement of leukemia patients from 1973 through 2014, using Surveillance Epidemiology and End-Result Survey Program (SEER) data. ICD-O-3 morphology codes were used to group leukemia into four types: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML). Survival analysis for each leukemia type stratified by race/ethnicity, age, sex was performed to generate relative survival probability estimates for the baseline time period of 1973 through 1979. Hazard ratios (HR) and respective 95% confidence intervals (CIs) for survival within subsequent 10-year time periods by race, age and sex were calculated using Cox proportional hazard models. Of the 83,255 leukemia patients for the current analysis, the 5-year survival of patients with ALL, AML, CLL, and CML during 1973–1979 were 42.0%, 6.5%, 66.5%, and 20.9%, respectively. Compared to the baseline, there were substantial improvements of leukemia-specific survival in 2010–2014 among African-American (81.0%) and Asian (80.0%) patients with CML and among 20–49 year of age with CLL (96.0%). African-American patients, those with AML and those older than 75 years of age had the lowest survival improvements. Asians experienced some of the largest survival improvements during the study period. Others, including African-American and the elderly, have not benefited as much from advances in leukemia treatment.

1 January 2018 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
FMFahad Mukhtar
Fahad Mukhtar
MIMmadili Ilozumba
Mmadili Ilozumba
OUOvie Utuama
Ovie Utuama
OCOguz Cimenler
Oguz Cimenler
Kaposi sarcoma (KS), one of the 3 AIDS-defining cancers, is a tumor that is associated with immunosuppression, and its presence in people with human immunodeficiency virus (HIV) warrants a diagnosis of HIV/AIDS.1 Kaposi sarcoma manifests as cutaneous purplish, reddish-blue, or dark brown or black macules, plaques, and nodules on the lower extremities,2-6 which has also been found to spread to the gastrointestinal tract, oral cavity, lungs, and lymph nodes.7-9 The different forms of identified KS are as follows: (1) classic KS, found commonly in Jewish, Mediterranean, and Middle Eastern HIV-negative elderly men5,10; (2) African KS, also known as endemic KS; (3) AIDS-associated KS, also known as epidemic KS, which is common in individuals with advanced immunodeficiency2; and (4) iatrogenic KS.8 Before the advent of AIDS, KS was found in elderly men.11 However, after the emergence of HIV/AIDS, it has become more common in younger patients with AIDS and weaker immune systems.12

4 November 2021 in Medical Care
Verified
Journal Article
Closed access
AAAbubakar-Sadiq B. Abdulai
Abubakar-Sadiq B. Abdulai
FMFahad Mukhtar
Fahad Mukhtar
Michael EhrlichMichael Ehrlich
Michael Ehrlich
Background: Previous data over an extended period indicated that Black and Hispanic patients waited significantly longer than their White counterparts to see a qualified practitioner in US emergency departments (EDs). Objective: The objective of this study was to assess recent trends and sources of racial and ethnic disparities in patient wait time to see a qualified practitioner in US EDs. Data Sources: Publicly available ED subsample of the National Hospital Ambulatory Medical Care Survey (NHAMCS), 2003–2017. Research Design: A retrospective cross-sectional analysis of a nationally representative sample of visits to US EDs from 2003 to 2017. Joinpoint statistical analysis and survey-weighted regression were used to assess changes in ED wait time by race/ethnic group over time. Principal Findings: For non-Hispanic White patients, median ED wait time increased annually by 1.3 minutes from 2003 through 2008, decreased by 3.0 minutes from 2008 through 2012, and decreased by 1.7 minutes from 2012 to 2017. For non-Hispanic Black patients, median wait time increased annually by 2.0 minutes from 2003 through 2008, decreased by 3.8 minutes from 2008 through 2015, and remained fairly unchanged from 2015 through 2017. For Hispanic patients, the trend in median wait time remained statistically unchanged from 2003 through 2009. It decreased by annually by 4.7 minutes from 2009 to 2012 and by 1.5 minutes from 2012 through 2017. By the end of 2017, median ED wait time decreased to under 20 minutes across all 3 groups. Conclusions: Over time, ED wait times decreased to under 20 minutes across all racial and ethnic groups between 2003 and 2017. Observed disparities were largely the result of where minority populations accessed care and disappeared over time.

20 February 2026 in Bipolar Disorders
Verified
Journal Article
Closed access
FDFaith Dickerson
Faith Dickerson
SKSabahat Khan
Sabahat Khan
AOAndrea Origoni
Andrea Origoni
KRKelly Rowe
Kelly Rowe
EKEmily Katsafanas
Emily Katsafanas
RYRobert Yolken
Robert Yolken